Abstract
Cancer is a widespread disease in our nation, characterized by a high occurrence rate. The use of tumor medications has been linked to an increased chance of cardiovascular complications, including a notable occurrence of heart toxicity. This has caused significant concern among healthcare professionals. This article provides a comprehensive compilation of drugs recognized for their potential to cause heart toxicity. Furthermore, extensive research has been conducted to investigate and categorize the effects of heart toxicity, with the purpose of promoting awareness, facilitating early intervention, and ultimately reducing the occurrence of heart toxicity. At the same time, there is an anticipation that Traditional Chinese Medicine (TCM) can capitalize on its unique attributes to address such ailments. To establish its effectiveness, it is crucial to carry out extensive clinical trials or retrospective analyses. The purpose of this article is to summarize the possible mechanisms of cardiac toxicity caused by commonly used chemotherapy drugs and summarize the possible mechanisms of adverse cardiac toxicity, laying the groundwork for subsequent research.
Abbreviations
BVZ, Bevacizumab; VEGF, vascular endothelial growth factor; CHF, Chronic heart failure; PGI2, Prostacyclin I2; NO, Nitric Oxide; ANT, Anthracyclines; DOX, doxorubicin; HER-2, human epidermal growth factor receptor-2; Bcl, B-cell lymphoma; ATP, Adenosine triphosphate; PI3K, Phosphatidylinositol3-kinase; AKT, Australasian Kidney Trials; ERK, extracellular regulated protein kinases; MAPK, mitogen-activated protein kinase; 5-FU, 5-fluorouracil; DNA, DeoxyriboNucleic Acid; Top, Recombinant Topoisomerase; TNF-α, Tumour necrosis factor-α; VTE, Venous Thromboembolism.
Data Sharing Statement
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request. We declared that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality.
Ethics Approval and Consent to Participate
This study was conducted in accordance with the declaration of Helsinki.
Acknowledgments
We would like to acknowledge the hard and dedicated work of all the staff that implemented the intervention and evaluation components of the study.
Disclosure
The authors declare that they have no competing interests in this work.